These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23692475)

  • 1. Classification of compounds with distinct or overlapping multi-target activities and diverse molecular mechanisms using emerging chemical patterns.
    Namasivayam V; Hu Y; Balfer J; Bajorath J
    J Chem Inf Model; 2013 Jun; 53(6):1272-81. PubMed ID: 23692475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging chemical patterns: a new methodology for molecular classification and compound selection.
    Auer J; Bajorath J
    J Chem Inf Model; 2006; 46(6):2502-14. PubMed ID: 17125191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of compounds in different local structure-activity relationship environments using emerging chemical patterns.
    Namasivayam V; Gupta-Ostermann D; Balfer J; Heikamp K; Bajorath J
    J Chem Inf Model; 2014 May; 54(5):1301-10. PubMed ID: 24803014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive activity profiling of drugs by topological-fragment-spectra-based support vector machines.
    Kawai K; Fujishima S; Takahashi Y
    J Chem Inf Model; 2008 Jun; 48(6):1152-60. PubMed ID: 18533712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DrugLogit: logistic discrimination between drugs and nondrugs including disease-specificity by assigning probabilities based on molecular properties.
    García-Sosa AT; Oja M; Hetényi C; Maran U
    J Chem Inf Model; 2012 Aug; 52(8):2165-80. PubMed ID: 22830445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of combinatorial clustering methods on pharmacological data sets represented by machine learning-selected real molecular descriptors.
    Rivera-Borroto OM; Marrero-Ponce Y; García-de la Vega JM; Grau-Ábalo Rdel C
    J Chem Inf Model; 2011 Dec; 51(12):3036-49. PubMed ID: 22098113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic identification of scaffolds representing compounds active against individual targets and single or multiple target families.
    Hu Y; Bajorath J
    J Chem Inf Model; 2013 Feb; 53(2):312-26. PubMed ID: 23339619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spline-fitting with a genetic algorithm: a method for developing classification structure-activity relationships.
    Sutherland JJ; O'Brien LA; Weaver DF
    J Chem Inf Comput Sci; 2003; 43(6):1906-15. PubMed ID: 14632439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules.
    Chen H; Yang Y; Engkvist O
    J Chem Inf Model; 2010 Dec; 50(12):2141-50. PubMed ID: 21077637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of support vector machine and artificial neural network systems for drug/nondrug classification.
    Byvatov E; Fechner U; Sadowski J; Schneider G
    J Chem Inf Comput Sci; 2003; 43(6):1882-9. PubMed ID: 14632437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions.
    Zernov VV; Balakin KV; Ivaschenko AA; Savchuk NP; Pletnev IV
    J Chem Inf Comput Sci; 2003; 43(6):2048-56. PubMed ID: 14632457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compound optimization through data set-dependent chemical transformations.
    de la Vega de León A; Bajorath J
    J Chem Inf Model; 2013 Jun; 53(6):1263-71. PubMed ID: 23654345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring CAMD technique performance. 2. How "druglike" are drugs? Implications of Random test set selection exemplified using druglikeness classification models.
    Good AC; Hermsmeier MA
    J Chem Inf Model; 2007; 47(1):110-4. PubMed ID: 17238255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects.
    Klekota J; Brauner E; Roth FP; Schreiber SL
    J Chem Inf Model; 2006; 46(4):1549-62. PubMed ID: 16859287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and evaluation of a molecular fingerprint involving the transformation of property descriptor values into a binary classification scheme.
    Xue L; Godden JW; Stahura FL; Bajorath J
    J Chem Inf Comput Sci; 2003; 43(4):1151-7. PubMed ID: 12870906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of compound mechanisms and secondary activities by BioMAP analysis.
    Berg EL; Kunkel EJ; Hytopoulos E; Plavec I
    J Pharmacol Toxicol Methods; 2006; 53(1):67-74. PubMed ID: 16040258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distance based algorithms for small biomolecule classification and structural similarity search.
    Karakoc E; Cherkasov A; Sahinalp SC
    Bioinformatics; 2006 Jul; 22(14):e243-51. PubMed ID: 16873478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of biologically active compounds by median partitioning.
    Godden JW; Xue L; Bajorath J
    J Chem Inf Comput Sci; 2002; 42(5):1263-9. PubMed ID: 12377018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.